ClinicaliQ Trial Snapshot
- A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT07789899.
- What is being tested: Two different formulations of GSK3862995B, an investigational medicine, are being compared to evaluate their pharmacokinetics (absorption, distribution, metabolism, and elimination), safety profile, and tolerability in healthy adults.
- Patient eligibility overview: The trial enrolls healthy adult participants with no significant medical conditions, representing a Phase I safety and tolerability assessment prior to evaluation in patient populations with disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will compare two formulations of the investigational medicine GSK3862995B in healthy adults. The study aims to assess how the body absorbs and processes the medicine, and to evaluate its safety and tolerability.
Eligibility Snapshot
- : * Participants who are generally healthy as determined by medical evaluation including medical history, physical examination laboratory tests, and cardiac monitoring * Body weight of at least 50.0 kilogram (kg) for male participants or at least 45.0 kg for female participants * Body Mass Index (BMI) within the range of 18.0 to 32.0 kilogram per square meter (kg/m^2) (inclusive) * Male, or female of non-childbearing potential (PONCBP)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.